Lundbeck to prepare FDA filing based on promising Alzheimer's data

On Monday morning, Lundbeck publicized top-line data from a phase III clinical trial of brexpiprazole.

Photo: Thomas Borberg/Politiken/Ritzau Scanpix

Lundbeck and the Danish pharmaceutical company’s Japanese partner, Otsuka Pharmaceuticals, had good news for investors on Monday morning.

Investors have been awaiting top-line data from a phase III study with the drug brexpiprazole as treatment for agitation in patients with Alzheimer’s, and the now published data reveals statistically significant improvements compared to placebo treatments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs